An illustration of amyloid plaques within the human brain, characteristic features of Alzheimer’s. By 2060, approximately 14 million Americans are expected to have the disease.
Kateryna Kon/Science Photo Library via Getty Images
FDA approval of aducanumab (Aduhelm) was contentious. Its submission to Health Canada for approval highlights concerns about evidence, independence and transparency in Canada’s drug approval process.
Alzheimer’s disease is characterized by progressive memory loss, spatial disorientation and many other cognitive and behavioural disorders that ultimately lead to a state of total dependence.
(Shutterstock)
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
In most cases, scientists are still unsure of what causes Alzheimer’s disease.
FGC / Shutterstock.com
After the failure of multiple drug trials the outlook for an Alzheimer’s drug is bleak. This shouldn’t be a surprise. We don’t know the cause or even how to diagnose the disease.